Literature DB >> 17074678

Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence?

Alberto Carmona1, Juan Domingo Alonso, Manuel de las Heras, Agustín Navarrete.   

Abstract

Paraneoplastic neurological syndromes constitute an unusual manifestation of cancer. The objective of this case report is to debate the association between rituximab therapy and Guillain-Barre syndrome. We present the case of a 57 years old patient, with diffuse large-B cell lymphoma in complete remission, who consulted our hospital because of symmetric lower extremity weakness, developed while being treated with a rituximab maintenance schedule. Our main conclusion is that plasma cell dysregulation due to rituximab should be clarified in future studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074678     DOI: 10.1007/s12094-006-0126-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  28 in total

1.  Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.

Authors:  Brigitte Buchwald; Raheleh Ahangari; Andreas Weishaupt; Klaus V Toyka
Journal:  Ann Neurol       Date:  2002-06       Impact factor: 10.422

Review 2.  [Immunotherapy of chronic inflammatory demyelinating polyneuropathy].

Authors:  J D Lünemann; K Prass; R Zschenderlein
Journal:  Fortschr Neurol Psychiatr       Date:  2004-12       Impact factor: 0.752

3.  Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.

Authors:  Irene M Ghobrial; Rafael Fonseca; Philip R Greipp; Emily Blood; Montserrat Rue; David H Vesole; Morie A Gertz
Journal:  Cancer       Date:  2004-12-01       Impact factor: 6.860

4.  Relapse of central nervous system Burkitt's lymphoma presenting as Guillain-Barre syndrome and syndrome of inappropriate ADH secretion.

Authors:  T G Phan; A Manoharan; D Pryor
Journal:  Aust N Z J Med       Date:  1998-04

Review 5.  Inflammatory neuropathies: update.

Authors:  C A Vedeler
Journal:  Curr Opin Neurol       Date:  2000-06       Impact factor: 5.710

Review 6.  [Guillain-Barré syndrome and non-Hodgkin's lymphoma. Report of one case and review of literature].

Authors:  N Magné; C Foa; P Castadot; J Otto; I Birtwisle-Peyrottes; A Thyss
Journal:  Rev Med Brux       Date:  2005 Mar-Apr

7.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors:  M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

Review 8.  Guillain-Barré syndrome: epidemiology, pathophysiology and management.

Authors:  Satoshi Kuwabara
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors:  R D Hadden; D R Cornblath; R A Hughes; J Zielasek; H P Hartung; K V Toyka; A V Swan
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

10.  Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.

Authors:  J K Bubien; L J Zhou; P D Bell; R A Frizzell; T F Tedder
Journal:  J Cell Biol       Date:  1993-06       Impact factor: 10.539

View more
  10 in total

1.  Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?

Authors:  Raquel Jaso; María Sierra; Jesús Calleja; Carmen Valero; Julio Pascual
Journal:  J Neurol       Date:  2009-11-22       Impact factor: 4.849

2.  Guillain-Barre Syndrome in a Patient with Primary Extranodal Intestinal Non-Hodgkin's Lymphoma: Paraneoplastic, Drug Induced or Coincidental?

Authors:  Aslı Kiyat Atamer; Kerem Okutur; Erdem Tüzün; Barış Hasbal; Ari Boyaciyan; Yakup Krespi; Gökhan Demir
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

Review 3.  Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

Authors:  I Steiner; G Rosenberg; I Wirguin
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

4.  Recurrent acute inflammatory demyelinating polyradiculoneuropathy following R-CHOP treatment for non-Hodgkin lymphoma.

Authors:  Jackson J Liang; Preet P Singh; Thomas E Witzig
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-04

5.  Neurological syndrome after R-CHOP chemotherapy for a non-Hodgkin lymphoma: what is the diagnosis?

Authors:  Dario Marino; Patrizia Farina; Antonio Jirillo; Giuseppe De Franchis; Marco Simonetto; Savina Maria Luciana Aversa
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

6.  Guillain-Barre Syndrome Associated with Gastric Cancer: Paraneoplastic Syndrome or Immunological Disorder?

Authors:  Maria Colantuoni; Elide Matano; Salvatore Alfieri; Sabino De Placido; Chiara Carlomagno
Journal:  World J Oncol       Date:  2011-01-01

7.  Guillain-Barré syndrome and hemophagocytic syndrome heralding the diagnosis of diffuse large B cell lymphoma: A case report.

Authors:  Qiao-Lin Zhou; Zhao-Kun Li; Fang Xu; Xiao-Gong Liang; Xing-Biao Wang; Jing Su; Yu-Feng Tang
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

8.  Variant Guillain-Barré Syndrome in a Patient with Non-Hodgkin's Lymphoma.

Authors:  R H Bishay; J Paton; V Abraham
Journal:  Case Rep Hematol       Date:  2015-08-11

Review 9.  Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors:  Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

10.  Gastric lymphoma complicated by phlegmonous gastritis and Guillain-Barré syndrome: A case report.

Authors:  Kodai Kuriyama; Yuki Koyama; Kazuma Tsuto; Natsuko Tokuhira; Hiroaki Nagata; Ayako Muramatsu; Muneo Oshiro; Yoshiko Hirakawa; Toshiki Iwai; Hitoji Uchiyama
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.